for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DarioHealth Corp

DRIO.OQ

Latest Trade

12.94USD

Change

0.34(+2.70%)

Volume

8,832

Today's Range

12.22

 - 

13.05

52 Week Range

3.03

 - 

22.34

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
12.60
Open
12.49
Volume
8,832
3M AVG Volume
5.92
Today's High
13.05
Today's Low
12.22
52 Week High
22.34
52 Week Low
3.03
Shares Out (MIL)
7.59
Market Cap (MIL)
97.69
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Dariohealth Says Selling Stockholders May Offer Up To 3.83 Million Shares Of Common Stock

DarioHealth Says Q2 Revenue Rose 8.2% To $1.79 Million

Dariohealth Corp Posts Q1 Loss Per Share Of $1.57

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About DarioHealth Corp

DarioHealth Corp. (DarioHealth) is a Digital Therapeutics (DTx) company. DarioHealth operates at the intersection of life sciences, behavioral science, and software technology to deliver integrated and engaging digital therapeutics interventions. The DTx products are centered around its users and include the Dario Blood Glucose Monitoring System and the Dario Smart Diabetes Management Solution, which are provided to its users in the form of a smartphone application that enables the delivery of content and periodical evidence-based reports; the DarioEngage platform, which provides support and two-way real-time connectivity between its users and their caregivers, and Dario Intelligence, which utilizes user data and is an analytics tool that can assist healthcare providers in the treatments and predictability of diseases. The Company’s services are available direct to consumers via online marketplaces including Amazon, Walmart, Best Buy and the Google and Apple app stores.

Industry

Medical Equipment & Supplies

Contact Info

8 Hatokhen St.

38900

Israel

+972.3.6222929

http://mydario.com

Executive Leadership

Yoav Shaked

Independent Chairman of the Board

Richard Allan Anderson

President, General Manager - North America

Erez Raphael

Chief Executive Officer, Director

Zvi Ben-David

Chief Financial Officer, Treasurer, Secretary

Dror Bacher

Chief Operating Officer

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-32.800

2018

-15.600

2019

-8.000

2020(E)

-4.410
Price To Earnings (TTM)
--
Price To Sales (TTM)
13.72
Price To Book (MRQ)
4.32
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-218.05
Return on Equity (TTM)
-141.37

Latest News

Latest News

BRIEF-DarioHealth Presents Studies Showing Improvements In Blood Glucose & Blood Pressure Control

* DARIOHEALTH PRESENTS NEW STUDIES DEMONSTRATING SUSTAINED IMPROVEMENTS IN BLOOD GLUCOSE AND BLOOD PRESSURE CONTROL IN USERS WITH DIABETES AND HYPERTENSION AT THE AMERICAN DIABETES ASSOCIATION'S 80TH SCIENTIFIC SESSIONS Source text for Eikon: Further company coverage:

BRIEF-DarioHealth Announces Two Remote Patient Monitoring Agreements And Commences Enrollment

* DARIOHEALTH ANNOUNCES TWO REMOTE PATIENT MONITORING (RPM) AGREEMENTS AND COMMENCES ENROLLMENT Source text for Eikon: Further company coverage:

BRIEF-Dariohealth Corp Posts Q1 Loss Per Share Of $1.57

* REVENUES FOR Q1 ENDED MARCH 31, 2020 WERE $1.67 MILLION, A 7.3% SEQUENTIAL DECREASE FROM Q4 ENDED DECEMBER 31, 2019

BRIEF-Dariohealth Corp - FDA Recognized Home-Use Blood Glucose Meters May Be Used By Patients With Diabetes Who Are Hospitalized Due To COVID-19

* DARIOHEALTH CORP - FDA RECOGNIZED HOME-USE BLOOD GLUCOSE METERS MAY BE USED BY PATIENTS WITH DIABETES WHO ARE HOSPITALIZED DUE TO COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Dariohealth Enters Partnership With Vitality To Accelerate Penetration Into Self-Insured Employer Market

* DARIOHEALTH ENTERS INTO A PARTNERSHIP WITH VITALITY TO ACCELERATE PENETRATION INTO THE SELF-INSURED EMPLOYER MARKET Source text for Eikon: Further company coverage:

BRIEF-Dariohealth Says Selling Stockholders May Offer Up To 4.65 Mln Shares Of Common Stock - SEC Filing

* DARIOHEALTH CORP SAYS SELLING STOCKHOLDERS MAY OFFER UP TO 4.65 MILLION SHARES OF OUR COMMON STOCK - SEC FILING Source : (http://bit.ly/3dgogJd) Further company coverage:

BRIEF-Dariohealth Reports Fourth Quarter Results

* DARIOHEALTH REPORTS FOURTH QUARTER AND YEAR END 2019 RESULTS

BRIEF-Dariohealth Says Compensation Board Approved 2 Year Extension Of CEO's Existing Employment Agreement

* DARIOHEALTH CORP - ON FEB 12, COMPENSATION BOARD APPROVED 2 YEAR EXTENSION OF EXISTING EMPLOYMENT AGREEMENT OF ITS CEO, EREZ RAPHAEL Source: (https://bit.ly/321A4JZ) Further company coverage:

BRIEF-DarioHealth Corp Reports Quarterly Loss Per Share Of $0.20

* QUARTERLY LOSS PER SHARE $0.20 Source text for Eikon: Further company coverage:

BRIEF-Dariohealth Corp Says Selling Stockholders May Offer From Time To Time Up To 8.5 Mln shares

* DARIOHEALTH CORP SAYS SELLING STOCKHOLDERS MAY OFFER FROM TIME TO TIME UP TO 8.5 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING Source text for Eikon: (http://bit.ly/2Fkuvtb) Further company coverage:

BRIEF-DarioHealth Receives U.S. FDA Clearance For iPhone 7, 8 And iPhone X Smart Glucose Meter

* DARIOHEALTH RECEIVES U.S. FDA CLEARANCE FOR IPHONE 7, 8 AND IPHONE X SMART GLUCOSE METER Source text for Eikon: Further company coverage:

BRIEF-DarioHealth Reports Fourth Quarter And Year End 2017 Results

* DARIOHEALTH REPORTS FOURTH QUARTER AND YEAR END 2017 RESULTS

BRIEF-DarioHealth Says Qtrly Reports On Form 10-Q For Quarter Ended March 30, 2017, June 30, 2017 And Sept 30, 2017 Should No Longer Be Relied Upon​

* DARIOHEALTH - QTRLY REPORTS ON FORM 10-Q FOR QUARTER ENDED MARCH 30, 2017, JUNE 30, 2017 AND SEPT 30, 2017 FILED WITH SEC SHOULD NO LONGER BE RELIED UPON

BRIEF-Dariohealth Launches Sales Of Dario Blood Glucose Monitoring System On Amazon Prime

* DARIOHEALTH LAUNCHES SALES OF DARIO™ BLOOD GLUCOSE MONITORING SYSTEM ON AMAZON PRIME

BRIEF-DarioHealth Wins Key Contract In Clinical Study

* DARIOHEALTH WINS KEY CONTRACT ENSURING ITS PLATFORM TO BE UTILIZED IN CLINICAL STUDY

BRIEF-Dariohealth - ‍ Received Therapeutic Goods Administration Mark For Its Lightning-Enabled Version Of Dario Blood Glucose Monitoring System

* DARIOHEALTH - RECEIVED THERAPEUTIC GOODS ADMINISTRATION MARK FOR ITS LIGHTNING-ENABLED VERSION OF DARIO BLOOD GLUCOSE MONITORING SYSTEM IN AUSTRALIA

BRIEF-Dariohealth Corp Q3 revenue $1.375 million

* Qtrly basic and diluted loss per share $0.30 Source text for Eikon: Further company coverage:

BRIEF-DarioHealth says selling stockholders may offer from time to time up to 2.9 mln shares of common stock

* DarioHealth Corp - selling stockholders may offer from time to time up to 2.9 million shares of co's common stock - SEC filing Source text: (http://bit.ly/2hQHQQg) Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up